Author

Mark Jelinek

Observed name: Mark D Jelinek

Institution: University of Pittsburgh

Observed institutions: University of Pittsburgh, UPMC Health System, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center

OpenAlex ID: A5113118997

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations

2025 · Matthew K Nguyen, Mark Jelinek, et al. · The Oncologist · 15

Normal CEA Levels After Neoadjuvant Chemotherapy and Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion Predict Improved Survival from Colorectal Peritoneal Metastases

2024 · Michael M. Wach, Geoffrey Nunns, et al. · Annals of Surgical Oncology · 9

Insight into Predictors of Cytoreduction Score Following Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy for Gastric Peritoneal Carcinomatosis Improves Patient Selection and Prognostic Outcomes

2024 · Ahmed B. Hamed, Rudy El Asmar, et al. · Annals of Surgical Oncology · 5

Tumor cell p38 inhibition to overcome immunotherapy resistance

2023 · Jason Luke, Rebekah Dadey, et al. · Research Square · 5

Differences in real-world pembrolizumab dosing patterns (every 3 weeks versus every 6 weeks) across a large cancer center network.

2023 · Divya Natesan, Priyanka Vinod Chablani, et al. · Journal of Clinical Oncology · 2

A Phase 1b/2 Study of the Efficacy and Safety of Combination Hydroxyurea and Dose-Escalated Erythropoietin for Treatment of Anemia in Sickle Cell Disease (ACHiEvE-SCD)

2024 · Titilope A Adeyemo, Nelly Kiriza, et al. · Blood · 1

Clinical and translational study of p38 inhibitor pexmetinib plus nivolumab following anti–PD-1/L1 failure in advanced solid tumors.

2026 · Matthew Nguyen, Andrew Stewart Poklepovic, et al. · Journal of Clinical Oncology

Clinical and Laboratory Outcomes During Versus After EPO Treatment in Patients With Sickle Cell Disease: Insights From ACHiEvE-SCD

2025 · Nelly K Kiriza, Titilope Adeyemo, et al. · Journal of sickle cell disease.

ASO Visual Abstract: Insight into Predictors of Cytoreduction Score Following Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy for Gastric Peritoneal Carcinomatosis Improves Patient Selection and Prognostic Outcomes

2024 · Ahmed B. Hamed, Rudy El Asmar, et al. · Annals of Surgical Oncology

A phase II trial of reirradiation combined with pembrolizumab in patients with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (HNSCC).

2024 · Dan Paul Zandberg, Jessica R Bauman, et al. · Journal of Clinical Oncology

ASO Visual Abstract: Normal CEA Levels After Neoadjuvant Chemotherapy and Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion Predict Improved Survival from Colorectal Peritoneal Metastases

2024 · Michael M. Wach, Geoffrey Nunns, et al. · Annals of Surgical Oncology

Works count: 11

Citation count: 37

H-index: 4

I10-index: 1